Cure SMA’s Webinar on the FDA Approval of Spinraza

There can’t be many people in the SMA community who haven’t heard the great news about the U.S. Food and Drug Administration’s (FDA) approval of the spinal muscular atrophy drug Spinraza (nusinersen). The drug can be used to treat SMA in babies, children, and adults.

Find out how Spinraza (nusinersen) works in treating SMA.

In this webinar from Cure SMA, Kenneth Hobby (the president of Cure SMA) and Valerie Cwik from the Muscular Dystrophy Association, along with representatives from Biogen explain the process of the FDA approving Spinraza. They also talk about the prescription information for the drug, the administration process for starting the treatment, and the cost of treatment.

Find out more about the FDA’s approval of Spinraza for the treatment SMA patients.

SMA News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

8 comments

    • Tim Bossie says:

      We can not give out any type of medical advice or direction in where to get the medicine. However, we would encourage you to talk with your doctor or pharmacist.

  1. Eugene J. Bienia says:

    I am 68years old,atrophy started in mid 80’s. Now using walker to get around, muscles getting weaker. Diagnosed SMA in 1991,Dr. Jon Brillman retired. Hospital Allegeny General, Pittsburgh, PA. Have an appointment with Dr. Rana on the 31’st of this month same hospital.

  2. Dr. Azza lotfi says:

    Hello
    I have a 3 years girl diagnosed with SMA..
    she lives in egypt .. how can we treat her with the new medication?

Leave a Comment

Your email address will not be published. Required fields are marked *